Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
UBX Unity Biotechnology Inc
- Stocks
- Healthcare
- NASDAQ: UBX
Price (delayed)
$0.7714
Market cap
$13.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.62
Enterprise value
$23.96M
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells
Highlights
UBX's debt is down by 17% year-on-year and by 5% since the previous quarter
The EPS is up by 39% year-on-year but it is down by 5% since the previous quarter
UBX's net income is up by 32% YoY but it is down by 6% from the previous quarter
UBX's equity has dropped by 103% since the previous quarter and by 101% year-on-year
The quick ratio has plunged by 60% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of UBX
Market
Valuations
Earnings
Shares outstanding
17.21M
Market cap
$13.28M
Enterprise value
$23.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$30.46M
Net income
-$27.5M
EBIT
-$27.5M
EBITDA
-$26.68M
Free cash flow
-$22.03M
Per share
Balance sheet
Liquidity
EPS
-$1.62
EPS diluted
-$1.62
Free cash flow per share
-$1.31
Book value per share
-$0.01
Revenue per share
$0
TBVPS
$1.8
Total assets
$30.35M
Total liabilities
$30.55M
Debt
$18.68M
Equity
-$205,000
Working capital
$8.58M
Debt to equity
-91.11
Current ratio
1.95
Quick ratio
1.87
Net debt/EBITDA
-0.4
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-65.2%
Return on equity
-273.7%
Return on invested capital
-60.6%
Return on capital employed
-129.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UBX stock price
How has the Unity Biotechnology stock price performed over time
Intraday
-1.73%
1 week
-4.17%
1 month
4.54%
1 year
-44.1%
YTD
-21%
QTD
-25.83%
Financial performance
How have Unity Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.46M
Net income
-$27.5M
Gross margin
N/A
Net margin
N/A
UBX's net income is up by 32% YoY but it is down by 6% from the previous quarter
UBX's operating income is up by 27% year-on-year and by 2.3% since the previous quarter
Price vs fundamentals
How does UBX's price correlate with its fundamentals
Growth
What is Unity Biotechnology's growth rate over time
Valuation
What is Unity Biotechnology stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 39% year-on-year but it is down by 5% since the previous quarter
UBX's equity has dropped by 103% since the previous quarter and by 101% year-on-year
Efficiency
How efficient is Unity Biotechnology business performance
UBX's return on equity has dropped by 134% year-on-year and by 69% since the previous quarter
UBX's ROIC is down by 26% since the previous quarter and by 20% year-on-year
UBX's ROA is down by 24% since the previous quarter and by 19% year-on-year
Dividends
What is UBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UBX.
Financial health
How did Unity Biotechnology financials performed over time
The current ratio has shrunk by 61% YoY and by 26% QoQ
The quick ratio has plunged by 60% YoY and by 25% from the previous quarter
UBX's equity has dropped by 103% since the previous quarter and by 101% year-on-year
UBX's debt is down by 17% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.